Should Biotechnology Stock Rubius Therapeutics Inc (RUBY) Be in Your Portfolio Friday?

Friday, December 30, 2022 03:03 PM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock Rubius Therapeutics Inc (RUBY) Be in Your Portfolio Friday?

Rubius Therapeutics Inc (RUBY) is near the middle in its industry group according to InvestorsObserver. RUBY gets an overall rating of 49. That means it scores higher than 49 percent of stocks. Rubius Therapeutics Inc gets a 56 rank in the Biotechnology industry. Biotechnology is number 48 out of 148 industries.

RUBY has an Overall Score of 49. Find out what this means to you and get the rest of the rankings on RUBY!

See Full RUBY Report

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 49 means the stock is more attractive than 49 percent of stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Rubius Therapeutics Inc Stock Today?

Rubius Therapeutics Inc (RUBY) stock is trading at $0.17 as of 3:00 PM on Friday, Dec 30, a drop of -$0.02, or -10.03% from the previous closing price of $0.19. The stock has traded between $0.16 and $0.20 so far today. Volume today is elevated. So far 1,851,666 shares have traded compared to average volume of 1,212,421 shares. Click Here to get the full Stock Report for Rubius Therapeutics Inc stock.